Loading...
Loading...
Browse all stories on DeepNewz
VisitAnother peer-reviewed paper confirming ETS2 pathway's role in IBD by mid-2025?
Yes • 50%
No • 50%
Publications in reputable scientific journals such as Nature, Science, or The Lancet
Researchers Discover Key Pathway in Inflammatory Bowel Disease in Gene Desert
Jun 5, 2024, 03:30 PM
Researchers at the Francis Crick Institute, in collaboration with UCL and Imperial College London, have made a significant discovery in the field of inflammatory bowel disease (IBD). They identified a new biological pathway involving an enhancer in immune cells called macrophages, which boosts a gene named ETS2, thereby increasing the risk of IBD. This breakthrough, described as the 'holy grail' by some researchers, opens up the potential for targeting this pathway using existing drugs. The findings, published in Nature, provide new insights into the genetic underpinnings of IBD, which affects millions of people worldwide. The discovery was made in a gene desert.
View original story
Yes • 50%
No • 50%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
USA • 25%
UK • 25%
Germany • 25%
Japan • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
GSK • 25%
Arthritis • 25%
Crohn's Disease • 25%
Multiple Sclerosis • 25%
Psoriasis • 25%
More effective than existing treatments • 25%
Equally effective as existing treatments • 25%
Less effective than existing treatments • 25%
Ineffective • 25%
Remains focused solely on liver diseases • 33%
Expands to include other organ-specific diseases • 33%
Expands to include systemic diseases • 33%
Germany • 25%
Japan • 25%
United Kingdom • 25%
United States • 25%
Novartis • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%